Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company pioneering tumor-activated therapies designed to target cancer precisely while reducing systemic side effects. This page serves as the definitive source for verified news and press releases related to XLO’s innovative immuno-oncology pipeline and strategic developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and research partnerships. Our curated collection includes announcements about XLO’s proprietary platform, engineered therapies (including cytokines, antibodies, and bispecifics), and collaborations advancing targeted cancer treatments.
Key updates cover advancements in tumor-activated IL-12, CTLA-4 inhibitors, and T cell engagers – all leveraging XLO’s focus on activating therapies exclusively within the tumor microenvironment. Bookmark this page to stay informed about developments that highlight the company’s scientific rigor and position in the competitive biotech landscape.
Xilio Therapeutics (Nasdaq: XLO) announced the grant of a non-qualified stock option for 55,000 shares to Kevin Brennan, the newly appointed Senior Vice President of Finance and Accounting, effective April 1, 2023. This stock option has an exercise price of $3.17 per share, matching the closing price on March 31, 2023, and will vest in increments over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize Mr. Brennan's role in the company. Xilio is focused on developing tumor-activated immuno-oncology therapies to improve treatment outcomes for cancer patients.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
